Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treatment of numerous solid tumors. KRAS mutations are driver neoantigens that are expressed in over 25% of all cancers and are thus regarded as ideal targets for Adoptive Cell Therapy (ACT). We have isola...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis Group
2021-01-01
|
| coleção: | OncoImmunology |
| Assuntos: | |
| Acesso em linha: | http://dx.doi.org/10.1080/2162402X.2021.1936757 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|